EPILEPSYGTX LIMITED

Company number 13415161 ·

Active

Executive summary

EpilepsyGTx Limited exhibits high solvency risk with negative working capital and minimal cash reserves at its first year-end. While regulatory filings are current and the company benefits from institutional shareholder support and experienced directors, the absence of operational revenue and limited financial history warrant close examination of funding and business viability before investment. Further due diligence on recent financials and strategic plans is essential to assess the company’s future stability.

Read the full AI analysis →

Shareholders' funds

-£4,953

Balance sheet as at 2021-12-31

View full accounts →

Overview

Company type
Private Limited Company
Incorporated
2021-05-24
Employees
0 (2021 accounts)
Registered office
Camburgh House, 27 New Dover Road, Canterbury, Kent, United Kingdom, CT1 3DN
Postcode
CT1 3DN
Capital
200 GBP
Accounts category
Small

Accounts

Last made up to
2025-12-31
Next due by
2027-09-30
Financial year end
31 December

Confirmation statement

Last statement dated
2026-05-23
Next due by
2027-06-06
View filing history →

Nature of business (SIC)

  • 72110 Research and experimental development on biotechnology

Officers 6 current · 4 resigned

Appointed 2025-12-23
Federica DRAGHI Director
Appointed 2025-12-23
Bernard RAVINA Director
Appointed 2025-08-01
UCLTF CORPORATE DIRECTORS LTD Corporate Director
Appointed 2023-02-17
Nicolas KOEBEL Director
Appointed 2022-11-09

View all officers and resignations →

Group structure

Controlled by UTF GENERAL PARTNER 2 LLP — since 2025-02-10

Controlled by UCL VENTURES LIMITED — since 2022-05-24

From persons-with-significant-control filings on the public register.

Data protection registration

Registered with the ICO as a data protection fee payer — ZC206138 (Tier 1), registered since 2026.

Information Commissioner's Office register of fee payers, licensed under the Open Government Licence.

At this address

1,181

companies are registered at this postcode →

Competitors Canterbury

This company ranks 21 among research and experimental development on biotechnology in Canterbury.

Full league table →